Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: February 7, 2023

Details for Patent: 8,859,610

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,859,610 protect, and when does it expire?

Patent 8,859,610 protects QBREXZA and is included in one NDA.

This patent has twenty-six patent family members in thirteen countries.

Summary for Patent: 8,859,610
Title:Crystalline glycopyrrolate tosylate
Abstract: Salts of glycopyrrolate, including solid forms thereof are herein disclosed. Methods of making glycopyrrolate salts and methods of treating hyperhidrosis with salts of glycopyrrolate are disclosed.
Inventor(s): Statler; John Allan (Redwood City, CA), Shaw; Anthony Adrian (North Vancouver, CA), Imbert; Delphine Caroline (Cupertino, CA), Nelson; Jennifer Leigh (Kokomo, IN), Andres; Patricia (West Lafayette, IN), McQueen; Lisa Lynn (West Lafayette, IN), Boerrigter; Stephan Xander Mattheus (West Lafayette, IN)
Assignee: Dermira, Inc. (Redwood City, CA)
Application Number:14/024,484
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,859,610
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,859,610

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,859,610

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014223172 See Plans and Pricing
Australia 2016269524 See Plans and Pricing
Canada 2902795 See Plans and Pricing
China 105026369 See Plans and Pricing
European Patent Office 2961734 See Plans and Pricing
European Patent Office 3473615 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.